Reviewing Rexahn Pharmaceuticals Inc. (RNN)’s and ContraFect Corporation (NASDAQ:CFRX)’s results

We will be contrasting the differences between Rexahn Pharmaceuticals Inc. (NYSEAMERICAN:RNN) and ContraFect Corporation (NASDAQ:CFRX) as far as profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Rexahn Pharmaceuticals Inc. N/A 0.00 14.37M -0.47 0.00
ContraFect Corporation N/A 0.00 37.68M -0.65 0.00

Table 1 demonstrates Rexahn Pharmaceuticals Inc. and ContraFect Corporation’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us Rexahn Pharmaceuticals Inc. and ContraFect Corporation’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Rexahn Pharmaceuticals Inc. 0.00% -119.8% -71.6%
ContraFect Corporation 0.00% -539.9% -113%

Risk and Volatility

Rexahn Pharmaceuticals Inc. has a beta of 0.7 and its 30.00% less volatile than S&P 500. Competitively, ContraFect Corporation’s beta is -0.49 which is 149.00% less volatile than S&P 500.

Liquidity

Rexahn Pharmaceuticals Inc. has a Current Ratio of 4.1 and a Quick Ratio of 4.1. Competitively, ContraFect Corporation’s Current Ratio is 7.2 and has 7.2 Quick Ratio. ContraFect Corporation’s better ability to pay short and long-term obligations than Rexahn Pharmaceuticals Inc.

Institutional and Insider Ownership

Institutional investors owned 9.3% of Rexahn Pharmaceuticals Inc. shares and 55.8% of ContraFect Corporation shares. About 0.2% of Rexahn Pharmaceuticals Inc.’s share are owned by insiders. Competitively, 10% are ContraFect Corporation’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Rexahn Pharmaceuticals Inc. 3.48% -16.3% -51.51% -67.96% -65.28% -42.13%
ContraFect Corporation -0.11% -7.88% -78.43% -77.25% -72.81% -69.97%

For the past year Rexahn Pharmaceuticals Inc. was less bearish than ContraFect Corporation.

Summary

Rexahn Pharmaceuticals Inc. beats on 5 of the 6 factors ContraFect Corporation.

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The companyÂ’s clinical stage drug candidates include RX-3117, which is in Phase IIa clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase IIa clinical study to treat patients with metastatic triple negative breast cancer. It is also developing Archexin, which has completed a pilot Phase IIa clinical trial for the treatment of pancreatic cancer; and is in Phase IIa clinical trial to treat patients with metastatic renal cell carcinoma. In addition, the company is involved in developing RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, which is in pre-clinical development stage used for the treatment of tumors. Rexahn Pharmaceuticals, Inc. is headquartered in Rockville, Maryland.

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.